Clinical Research Currents
  • Home
  • About Us
  • News
    • AI & Machine Learning
    • Alzheimers & Dementia
    • Animal studies
    • Clinical development
    • Clinical science
    • Contract Research Organization
    • Disparities
    • Education
    • Employment
    • FDA
    • FDA Guidance
    • FDA Guidance Documents
    • History
    • Immunotherapy
    • Innovation
    • International
    • Interview
    • Investigator
    • Mobile
    • NIH
    • Operations
    • Patient Perspective
    • Political economy
    • Pre-clinical
    • Precision Medicine
    • Recruitment
    • Regulatory
    • Study Design
    • Wearables
    • Trends
    • Real World Data/Evidence
    • Blockchain
    • Clinical trials
    • Adverse events
    • Technology
  • Calendar
  • Newsletter
  • Resources

2021 Update

Clinical Research Currents has temporarily suspended publication.
Learn about our new clinical trials startup, Sparrow Search, connecting patients with clinical trials.

Bias in referral to Phase 1 cancer studies

www.ncbi.nlm.nih.gov

April 6, 2019
Clinical trials, Disparities, Early phase

This case-control registry study in Denmark found that novel anticancer therapies seemed to be tested on a socially selected group of patients with cancer. Patients with long distance to the Phase 1 unit, less education, and belonging to the lowest income quintile were less likely to be referred to Phase 1 trials. (PubMed)

Will the FDA update the IND pathway?

www.modernhealthcare.com

December 7, 2018
Early phase, FDA

The U.S. FDA has initiated a review of its Investigational New Drug (IND) application process whereby researchers are permitted to begin clinical trials in humans.  Depending on the results of this review, the IND application process may be changed, especially if the study uncovers widespread safety concerns. (Modern Healthcare)

Off-label use of drugs based on flimsy evidence

www.bmj.com

April 3, 2018
Clinical science, Early phase, Ethics

Clinical trials that explore the repurposing of drugs for off-label uses are common, but without a commitment to rigorously testing the hypotheses generated by these exploratory trials, drugs used off-label are costly and may be ineffective. Ethics committees should devise measures that encourage coupling of exploratory testing with confirmatory trials. (British Medical Journal)

Phase 1 pediatric cancer trials are therapeutic. True? Or, is this “a noble lie”?

www.translationalethics.com

March 8, 2018
Early phase, Ethics, Oncology

It’s this author’s view that it may be a mistake to think of early phase trials as having a therapeutic impetus.  U.S. regulations require that, when we enroll children, we view phase 1 trial participation as therapeutic. However, a recent meta-analysis concluded that phase 1 trials in children cannot generally be presented as having a therapeutic risk/benefit. Thus, phase 1 trials in children cannot be reconciled with research regulations. (translationalethics.com)

More patients are joining Phase 1 cancer trials – to get access to new experimental treatments

scienmag.com

March 8, 2018
Early phase, Oncology

The importance of early stage clinical trials in oncology is increasing. Historically, cancer patients participated in phase 1 trials because this was the only option for those with advanced cancer that would not respond to standard treatment. Today, more patients are interested in participating not because it is a last resort for them, but because they gain access to new treatment alternatives to chemotherapy, and there are larger trials which benefit more patients. (SCIENMAG)

Subscribe to our Newsletter

Get the latest clinical research news delivered straight to your inbox each week.

Submit a Story

Do you have a story you'd like to feature on our website? Share it with us today!

Submit your story

 Join our LinkedIn Group

© 2023 Clinical Research Currents · All Rights Reserved